Immunotherapy before and after surgery shows promise for lung cancer
NCT ID NCT07450183
First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This phase II trial tests the drug cemiplimab, an immunotherapy, given before and after surgery for people with early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. About 33 participants will receive cemiplimab for three cycles, then undergo surgery, followed by ten more cycles. The main goal is to see how many patients have no cancer left in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab
- What this could lead to
- If successful, this could show that adding cemiplimab around surgery helps control lung cancer and may improve long-term outcomes.
- What could go wrong
- This is a small, early-phase trial with only 33 participants. It may not prove effective, and side effects from immunotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henry Ford Health
Detroit, Michigan, 48202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Family support may be key to easing lung cancer surgery stress
- Can a drop of blood predict disease years before it strikes?
- Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer